Precision genetic therapy aims to slow rare brain disease
NCT ID NCT07215416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a drug called atipeksen for people with Ataxia-Telangiectasia (A-T), a rare genetic disease that affects movement and coordination. The drug is designed to fix a specific genetic error in the ATM gene and is given via spinal injection. The study will enroll 10 participants to check if the treatment is safe and can slow the progression of neurological symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atipeksen (a genetic therapy given via spinal injection)
- What this could lead to
- If successful, this could slow or stop the worsening of neurological symptoms in people with a specific form of Ataxia-Telangiectasia, improving daily function and quality of life.
- What could go wrong
- This is a very early, small trial (10 participants) testing safety and effectiveness. The therapy only works for people with a specific genetic mutation, and it may not work for everyone or could cause side effects from the spinal injections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATAXIA TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Children's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could early markers unlock treatments for a rare childhood disease?
- Experimental drug shows promise for rare genetic disorder
- Large study looks at how a 25-Gene cancer test affects patients and families
- Continued EryDex treatment studied in rare neurological disorder
- Could red blood cells deliver a steroid to ease a rare brain disorder?
- New study hopes to outsmart pancreatic cancer by gathering clues